Title: Determination of LMP744 (NSC 706744) Levels in Human Plasma and Urine Samples from an NCI Phase I Trial.POP: 04/10/2017 - 04/09/2018

标题：NCI I 期试验中人血浆和尿液样本中 LMP744 (NSC 706744) 水平的测定。POP：04/10/2017 - 04/09/2018

• 批准号: 10335107
• 负责人: JULIE EISEMAN
• 金额: $ 13.41万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-10 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10335107
• 关键词: Clinic; Clinical Trials; Developmental Therapeutics Program; Evaluation; Human; Plasma; Sampling; Series; Site; Topoisomerase-I Inhibitor; Urine; analog; phase I trial

A series of indenoisoquinoline inhibitors of topoisomerase I have been extensively studied by the NCI, and two of these compounds (LMP400 and LMP 776) have previously been investigated in human clinical trials.

拓扑异构酶I的一系列茚并异喹啉抑制剂已被NCI广泛研究，其中两种化合物（LMP 400和LMP 776）先前已在人体临床试验中进行了研究。